tiprankstipranks
Immutep Stock (NASDAQ:IMMP) Soars on Fast-Track Nod for Eftilagimod
Market News

Immutep Stock (NASDAQ:IMMP) Soars on Fast-Track Nod for Eftilagimod

Shares of biotechnology company Immutep (NASDAQ:IMMP) are soaring today after the combination of its eftilagimod and Merck’s (NYSE:MRK) Keytruda received fast-track status from the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC).

Importantly, eftilagimod also provides a chemotherapy-free alternative for patients suffering from NSCLC as well.

Is Immutep Stock a Good Buy?

IMMP stock only has one analyst covering it, giving it a Moderate Buy rating based on one Buy. However, its price target of $8 still implies a massive 379.33% potential upside for the stock.

That’s after a nearly 58% slide in the price of IMMP stock over the past year.

Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles